Evaluating only Vor Biopharma’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Vor Biopharma founded in Cambridge, MA by Eyal Attar to engineer hematopoietic stem cells resistant to CD33-targeted therapies.
FUNDING
IPO on Nasdaq raises $154M; trem-cel platform generates excitement as potential AML cure enabling safer conditioning.
PRODUCT LAUNCH
Phase 1 VOR33 data released; overall response rate of 40% disappoints analysts expecting >60% in heavily pretreated AML.
LAYOFF
Vor Biopharma lays off 55% of workforce (70 employees), halts clinical expansion, explores strategic alternatives.
Full Analysis
Free · no account needed
Documented cause
Vor Biopharma, a Cambridge-based engineered stem cell therapy company targeting AML with its trem-cel platform, underwent severe restructuring in November 2024. CEO Robert Ang laid off 55% of staff — approximately 70 employees — after its lead program VOR33 showed only modest responses in Phase 1 AML patients who had exhausted other therapies. The company had raised $305M including a $154M IPO in 2021. Remaining cash of $97M was insufficient to fund the pivotal trial needed for approval.
Lesson
“Engineered HSC therapies must demonstrate durable remissions in Phase 1 to justify $200M+ pivotal trial investment.”